Dec 11, 2020 10:55am In response to the COVID-19 pandemic, the company has expanded its data-driven approach to diagnostics by entering the infectious disease market, starting with COVID-19. (Tempus) Tempus, a company that uses artificial intelligence to advance precision medicine, banked $200 million financing rounds that includes a massive valuation of $8.1 billion dollars. The company announced the series G-2 round Thursday. Investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price. The company was founded in 2015 by...